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Abstract.  The pathogenicity of the human c-erbB-2 
oncogene was evaluated in transgenic mice. A  DNA 
sequence comprising the promoter-enhancer region of 
the MMTV LTR and a constitutively activated allele 
of the human c-erbB-2 growth factor receptor gene 
was introduced into the germ line of mice. Expression 
of the transgene was observed in kidney, lung,  mam- 
mary gland,  salivary gland,  Harderian gland,  and in 
epithelial ceils of the male reproductive tract.  All 
transgenic mice expressing the c-erbB-2 receptor died 
within four months of birth.  Histopathological analysis 
suggests that preneoplastic lesions in kidney and lung 
most likely caused organ failure and the early death of 
the transgenic  mice.  Focal dilatation and atypical 
proliferation of the tubular epithelial cells was found 
in the kidney. These hyperplastic lesions were found 
adjacent to normal tubules. 
Immunohistochemistry  showed that normal renal 
structures were completely negative for c-erbB-2 pro- 
tein expression.  Atypical pseudopapillary proliferation 
of bronchial and bronchiolar epithelial cells narrowed 
the bronchial lumen in lung.  Alveoli appeared normal. 
The expression of c-erbB-2 protein was strictly limited 
to the proliferating epithelial cells and not detected in 
normal tissue.  The mammary glands of two parous 
mice were underdeveloped, lacking lobular-alveolar 
structures and were lactation deficient.  Only a few 
ducts were interspersed in the fat pad.  A virgin mouse 
developed a focal adenocarcinoma infiltrating the 
mammary fat pad.  Expression of the c-erbB-2 protein 
was enhanced in the proliferating epithelial cells. 
Transgenic males were sterile.  Epithelial hyperplasia 
and hypertrophy in the epididymis, vas deferens and 
seminal vesicles was found.  The transgene is not uni- 
formly expressed in the tissues where the MMTV 
LTR is transcriptionally  active. The scattered trans- 
gene expression invariably coincides with epithelial 
hyperplasia. 
T  RANSMEMBRANE  glycoproteins  with tyrosine specific 
protein kinase activity confer signals from extracellu- 
lar ligands, such as polypeptide hormones and growth 
factors, to the intracellular  signal transduction  and transcrip- 
tion  machinery.  The  ligand  activated  receptor  molecules 
regulate central  cellular functions such as growth and dif- 
ferentiation.  Mutated forms of these receptors as well as 
their deregulated expression can contribute to cellular trans- 
formation (Ullrich and Schlessinger,  1990; Aaronson,  1991; 
Hanks, 1991). The c-erbB-2 gene, the homologue of the rat 
c-neu gene, encodes a typical representative of this receptor 
gene family. Investigated in different cell types, and probed 
under different circumstances it was found to contribute to 
cell proliferation,  cell differentiation,  and to exert transform- 
ing potential. 
The human c-erbB-2 gene was identified due to its similar- 
ity with the EGF receptor gene;  its homologue is the rat 
c-neu gene  (Schechter  et al.,  1984,  1985;  Semba et al., 
1985).  The two receptors are structurally related and have 
overlapping  as well as distinct biological effects (di Fiore et 
al., 1990; Segatto et al., 1991). The c-erbB-2 gene encodes 
a  185-kD  transmembrane  glycoprotein,  gp185  c-erbB-2 
(Coussens et al.,  1985; Yamamoto et al.,  1986). It is com- 
monly expressed in fetal epithelial cells of kidney, lung, gas- 
trointestinal  tract, placenta at term, and to a lesser degree 
in normal adult tissues (Gullick et al.,  1987; Kokai et al., 
1987; Mori et al.,  1989; Press et al.,  1990). 
The c-erbB-2 receptor can be activated  by binding  to its 
ligand heregulin  (Holmes et al., 1992) or neu differentiation 
factor (Wen et al.,  1992). Activation causes an increase in 
the tyrosine phosphorylation of the receptor and a mitogenic 
response, e.g., in the human breast carcinoma cell line SK- 
BR-3 (Holmes et al.,  1992).  Differentiation-specific  effects 
were observed in the human breast carcinoma cell line AU- 
565 upon ligand activation of the receptor.  These include al- 
terations  in cell morphology,  the synthesis of milk compo- 
nents,  an  increase  in  the  nuclear  size,  inhibition  of cell 
growth,  and  induction  of DNA polyploidy (Peles et al., 
1992).  Differentiation  promoting  effects of c-erbB-2 recep- 
tor activation,  e.g., conferal of sensitivity towards the action 
of lactogenic hormones, have been observed in the mouse 
mammary  epithelial  cell line  HCll  (Hynes et al.,  1990; 
Taverna et al.,  1991). 
Both the human c-erbB-2 gene and the rat c-neu gene have 
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tumor formation in vivo. Amplification of the c-erbB-2 gene 
and over-expression of its gp185 product has been shown to 
occur in human adenocarcinomas of the breast and ovary 
(Slamon et al., 1989), as well as in gastric (Yonemura et al., 
1991) and nonsmall cell lung adenocarcinoma (Kern et al., 
1990). c-erbB-2 over-expression is predictive of clinical out- 
come and associated with an unfavorable prognosis (Slamon 
et al., 1987, 1989; Varley et al., 1987; Berger et al., 1988; 
Borg et al.,  1990).  The rat c-neu gene was isolated as a 
dominantly transforming oncogene from a  chemically in- 
duced rat neuroblastoma (Shih et al., 1981). The activation 
of the c-neu gene was shown to be due to the mutation of 
a valine residue to glutamic acid in the transmembrane do- 
main (Schechter et al.,  1984;  Bargmann et al.,  1986a,b). 
This mutation results in an oncogenic variant which displays 
constitutive high phosphorylation on tyrosine and is func- 
tionally equivalent to the ligand stimulated receptor (Yarden, 
1990).  The c-erbB-2 gene is not mutated in human carci- 
nomas and its transforming activity is due to gene amplifica- 
tion and the resulting overexpression of the gene product. It 
is also highly phosphorylated on tyrosine in primary breast 
tumor cells which overexpress the gene (Wildenhain et al., 
1990). 
Transgenlc mice have become useful models for the study 
of oncogenes. The tissue-specific action of  oncogenes in vivo 
and  their  causality  in  carcinogenesis  have  been  demon- 
strated. Consistent patterns of widespread cell proliferation 
and dysplasia that precede tumor development have been de- 
scribed (Adams and Cory, 1991). To study the influence of 
the activated c*erbB-2 oncogene on cell proliferation, differ- 
entiation and transformation, we introduced a constitutively 
activated, transforming allele of the human c-erbB-2 on- 
cogene under the control of the long terminal repeat of the 
mouse mammary tumor virus, MMTV LTR, into transgenic 
mice. Experiments have been described previously in which 
the activated rat c-neu gene and the normal c-erbB-2 allele 
under the control of  the MMTV LTR have been used (Muller 
et al., 1988; Bouchard et al., 1989; Suda et al., 1990).  The 
transgenes introduced in these earlier studies are similar, but 
not identical to the one described here.  Our experiments 
confirm some of the earlier conclusions, clarify conflicting 
claims and extend the observations. We show that transgene 
expression is not uniform in tissues in which the MMTV 
LTR is transcriptionally active and invariably correlates with 
epithelial hyperplasia. Non-expressing normal cells in lung, 
kidney, mammary, and salivary glands reside side-by-side 
with expressing hyperplastic cells. Mammary cells are most 
prone to transformation and focal adenocarcinomas occur 
very early. The life span of the transgenic mice is limited by 
the severe preneoplastic lesions in kidney and lung which re- 
sult in organ failure. 
Materials and Methods 
Construction of the MMTV LTR c-erbB-2 Gene 
The MMTV LTR contained within a  1.7-kb SalI-HindIII fragment (Jaggi 
et al., 1986) was converted to a SalI-EcoRI fragment by linker ligation. The 
HindIII sites of the activated c-erbB-2 (VE) fragment (Suda et al.,  1990) 
were converted into EcoRI sites and linked to the EcoRI sites of MMTV 
LTR and to the splicing and polyadenylation signal from SV-40 and cloned 
into the pSP72 plasmid as depicted in Fig. 1. Standard techniques were used 
in the cloning experiments (Samhrook et al.,  1989). 
Generation of Transgenic Mice 
Transgenic mice were generated and analyzed as described (Botteri et al., 
1987). Fertilized eggs used for microinjection were derived from C57BL/ 
6xCB6F1  mice. 
Analysis of the Transgene RNA Transcript 
Mouse tissues were removed at necropsy and immediately frozen in liquid 
nitrogen. RNA was prepared by the single step method of Chomczynski and 
Sacchi (1987).  15 gg of total RNA per lane were electrophoresed on 1% 
agarose-formaldehyde gels, transferred to nylon membranes (Gene screen 
plus) and hybridized either with the 1.6-kb SV-40 fragment or the 4.4-kb 
c-erbB-2 fragment labeled with c~-[32p]dCTP by the random priming pro- 
cedure (Boehringer Mannheim Corp., Indianapolis, IN). Prehybddization, 
hybridization, and washes were carded out as described by Sambrook et al. 
(1989). 
Histology 
Complete autopsies were performed and both gross and microscopic exami- 
nation were done. Tissues for histology and immunohistology were fixed 
in 10% buffered formalin and embedded in paraffin,  sectioned at 4/zm, 
stained  with  hematoxylin  and  eosin,  and  examined  for  pathological 
findings. 
Immunohistology 
For the detection of the c-erbB-2 protein, paraffin embedded tissues were 
sectioned at 4/zm, deparaliinized, and immunostaining was performed with 
the  biotin-streptavidin amplified  detection  system  according  to  StrAvi- 
Gen  TM super sensitive universal immunostaining kit (Bio Genex Laborato- 
ries, San Ramon, CA). The specific antibody used to detect c-erbB-2 pro- 
rein was the polyclonal antiserum 21N, raised against the COOH-terminus 
of the c-erbB-2 protein (GuUick et al., 1987). The enzyme used was alkaline 
phosphatase and to detect the bound phosphatase complex the chromogen 
Fast red was applied. All sections were counterstained with Mayer's hema- 
toxylin. 
Results 
Generation of  MMTV LTR c-erbB-2 Transgenic Mice 
We derived transgenic mouse lines expressing the activated 
human c-erbB-2 gene. The transforming gene product of the 
c-erbB-2 gene differs from its normal counterpart by a single 
amino acid substitution (valine 659 to glutamic acid) within 
the transmembrane domain (Suda et al., 1990) and is homol- 
ogous to the mutant rat c-neu oncogene. A eDNA encoding 
the activated human c-erbB-2 (VE) protein was linked to the 
MMTV LTR promoter/enhancer (Jaggi et al., 1986) and the 
splicing and polyadenylation  sequences from SV-40 (Fig. 1). 
The biological activity and transformation ability of this 
MMTV  LTR c-erbB-2 (VE)  construct was  confirmed in 
transfected NIH-3T3 cells. Glucocorticoid hormone depen- 
dent cell transformation in vitro and tumor formation in nude 
mice were observed (data not shown). 
Transgenic mice were generated. A 7.7-kb SaR fragment 
comprising the MMTV LTR c-erbB-2 hybrid gene was mi- 
croinjected into the  male pronucleus  of fertilized mouse 
eggs. 14 positive animals carrying between 2 and 50 copies 
of the transgene per cell, were identified by Southern blot 
analysis of DNA from tail biopsies (data not shown). One 
of the positive animals, TM1631, contained two separate un- 
linked insertions of the transgene. Only one positive female 
mouse, TMl165, was able to establish a transgenic line and 
transmit the transgene to her progeny in a typical Mendelian 
fashion. These mice, however, did not express the transgene 
(see below). Of the six positive male animals mated, only 
one sired a litter. However,  this animal was genetically too- 
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Figure 1.  Schematic representation of the MMTV LTR c-erbB-2 
transgene. (ra) The c-erbB-2 eDNA encoding the activated human 
c-erbB-2 protein;  ([]) The MMTV LTR promoter with the tran- 
scription initiation site; (s~) The termination signal from the SV-40 
early gene. Relevant restrictions sites are identified. 
saic and the transgene was not inherited in its progeny. The 
other five positive males failed to sire offspring. This is most 
likely explained by the finding that these animals developed 
severe hyperplasia and hypertrophy of the epididymis and 
seminal vesicles (discussed below). Four positive females, 
TM1630, TMl162, TM1624, and TM1723 were mated suc- 
cessfully and carried pups to term (Table I). All pups died 
one  day  after  birth,  most  likely  because  the  transgenic 
mothers were unable to nurse their young (discussed below). 
Eight of the positive transgenic mice died unexpectedly of 
unknown causes between one and four months of age and 
were not available for necropsy. Two males, TM1623 and 
TM1696, showed symptoms of respiratory disease and were 
sacrificed at the age of 4 and 8 wk, respectively. We also ex- 
amined three apparently healthy females: two ll-wk-old and 
a 9-wk-old positive females, TM1631, TM1624, and TM1723. 
TM1631 was a virgin mouse. TM1624 and TM1723 became 
pregnant and delivered a  litter at term,  but all pups  died 
within 1 d. These two mothers were sacrificed 2 d later and 
analyzed together with the other five positive animals.  We 
investigated transgene expression in different tissues and car- 
ried out histological and immunohistological evaluations. 
Table L Transgenic MMTV  LTR c-erbB-2 Mice 
Life span (weeks) 
Pups 
Mouse-Nr  Sex  Died  Sacrificed  Pregnant  survival 
TM 1724  f 
TM1755  f 
TM1613  m 
TM1621  m 
TM1630  f 
TMl166  m 
TM1609  m 
TMl162  f 
TM1623  m 
TM1696  m 
TM1723  f 
TM1631  f 
TM1624  f 
TM1165"  f 
TMllFI*  f 
4 
7 
9 
10 
10 
12 
13 
16 
4 
8 
9 
11 
11 
20 
14 
+ 
+ 
* Only established line,  but not expressing. 
$ Offspring from TMl165. 
Figure 2.  Detection of MMTV LTR c-erbB-2 RNA in transgenic 
mice.  15/~g of total RNA from various tissues was analyzed on 
Northern blots for the presence ofc-erbB-2 transgene specific RNA 
with the 1.6-kb  SV-40  fragment (A) or the 4.4-kb c-erbB-2 fragment 
(B). The equal loading of RNA was verified by methylene blue 
staining. 
Tissue Specific Expression of the MMTV LTR 
c-erbB-2 Transgene 
Transcription from the MMTV LTR promoter is known to 
be  regulated  by  different classes  of steroid  hormones  in 
transfected cultured cells (Cato et al., 1987). Its potential to 
direct the expression of transgenes has been evaluated. De- 
spite the implication in its name, the MMTV LTR is not ex- 
clusively active in mammary gland cells. High levels of ex- 
pression have been detected in mammary epithelium, but 
expression was also found in the epithelial cells of salivary 
glands,  lung,  kidney, seminal vesicles, testes,  and also in 
lymphoid cells  in  spleen and  thymus  (Choi  et al.,  198% 
1988; Stewart et al.,  1988; Henrard et al.,  1988; Ross et al., 
1990). 
To determine the MMTV LTR c-erbB-2 transgene expres- 
sion in mouse organs, RNA was analyzed by Northern blot- 
ring.  We used two hybridization probes to detect transgene 
expression, the  1.6-kb  SV-40-specific DNA  fragment and 
the 4.4-kb c-erbB-2 specific DNA fragment (shown in Fig. 
1). The 1.6-kb SV-40 fragment detects exclusively the trans- 
gene transcript (predicted length 5.2 kb). The 4.4-kb c-erbB-2 
fragment recognizes the transgene as well as the endogenous 
mouse c-erbB-2 gene transcript (predicted length 4.8 kb). 
The  Northern  blot  analysis  of the  RNA  from tissues  of 
TM1631,  a  virgin  female,  and  TMllF1  an  offspring  of 
founder TMl165,  is shown in Fig.  2 A.  The hybridization 
was carried out with the 1.6-kb SV-40 DNA probe. A high 
level of expression of the 5.2-kb transgene transcript was 
found in kidney and lung of TM1631, but not in TM11F1 and 
wild-type control mice. TMllFI is an offspring of TMl165, 
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c-erbB-2 Mice 
Tissue 
Mouse No/  Mammary 
gender  Kidney  Lung  gland  Muscle Spleen  Brain  Liver 
TM1623  m  +  + +  +  +  ND  .... 
TM1624  f  +  +  +  +  +  -*  -  +  +  -  - 
TM1631  f  +++  ++  ...... 
TM1696 m  +  +  ND  ND  +  +  ND  - 
TM1723  f  -*  -*  +  +  +  ND  -  ND  - 
TM1165  f  ....... 
TM11F1  f~  ....... 
wild-type f  -  -  -  ND  -  -  - 
Northern blot analysis was performed on 15/~g of total  RNA extracted from 
a variety of organs from MMTV-c-erbB-2 mice. Relative levels of transgene 
expression are indicated by: +, low;  + +, intermediate; or + + +, high; ND, 
not done. 
* Positive expression in immunohistology. 
No significant lesions in histology. 
§ Offspring from TMlI65. 
the only founder mouse capable  of producing transgenic 
progeny. 
The  pattern  of tissue-specific  transgene  expression  in 
TM1631 was confirmed using the c-erbB-2 probe (Fig. 2 B). 
The endogenous mouse c-erbB-2 gene transcript was de- 
tected only in lung and kidney of all transgenic mice which 
also expressed the transgene. The endogenous mouse c-erbB-2 
transcript was not found in lung and kidney RNA of wild- 
type controls. 
The results of the Northern blot analysis of all transgenic 
MMTV LTR c-erbB-2 mice investigated are summarized in 
Table  II.  The  positive  animals  TM1623,  TM1624,  and 
TM1631  showed high levels of transgene expression in lung 
and kidney while TM1696  showed low expression in these 
organs.  TM1624  and TM1696  displayed in addition high 
transgene expression in the spleen. A high level of transgene 
expression in the  mammary gland was  only observed  in 
TM1723.  Transgene-specific RNA expression in the other 
investigated  mammary  glands  was  barely  detectable  by 
Northern blot analysis. The immunohistochemical analysis 
of the tissues was more informative (described below). The 
deregulated c-erbB-2 gene expression was consistently high 
in lung and kidney of four independent transgenic animals. 
We suspected that the early death of the transgenic animals 
might be causally related to these observations. For this rea- 
son we carded out histological and immunohistochemical 
analyzes of these organs. 
Histological and Immunohistochemical Analysis 
of  Lung and Kidney Tissue 
Consistent phenotypic abnormalities were detected only in 
tissues in which the Northern blot analysis had indicated 
transgcne expression (Tables II and III). Histological exami- 
nation revealed that the lungs were dominated by mild to se- 
vere hyperplasia of bronchial and bronchiolar epithelium 
with marked basophilia. Pronounced, atypical, pseudopapil- 
lary proliferation of epithelial cells caused partial or com- 
plete obstruction of the bronchial lumen. Alveoli did not 
show significant  lesions (compare Fig. 3, A and B). To deter- 
mine the cellular distribution pattern of  the c-erbB-2 protein, 
we used the polyclonal antiserum 21N,  raised against the 
COOH-terminus of the  c-erbB-2 protein  (Gullick et al., 
1987). Immunostaining showed that expression was limited 
to the proliferating epithelial cells (Fig. 3 C). Cells in adja- 
cent normal tissue could not be stained or stained only very 
weakly. 
In kidney the predominant phenotypic alterations were 
found in the cortex (Fig.  3 E).  Multifocal, severe hyper- 
plasia of renal tubules resulting in dilatation and microcystic 
changes were observed. The tubules revealed atypical prolif- 
eration of tubular epithelial cells and some even showed 
pscudopapillary intraluminal proliferation. It can be seen at 
Table III. Summary of  Phenotypic Abnormalities in MMTV LTR c-erbB-2 Transgenic Mice 
Epididymis/  Lacrimal/ 
Mouse No/  Salivary  Seminal  Harderian 
gender  Kidney  Lung  Mammary gland  gland  Spleen  vesicles  gland 
TM1623  m  dilated tubules  hyperplasia  NA  ND  NSL  hyperplasia  ND 
hyperplasia  hypertrophy 
TM1624  f  dilated tubules  hyperplasia  development incomplete/  hyperplasia  diffuse malignant  NA  ND 
hyperplasia  nonlactating  mastocytosis 
hyperplastic nodule 
TM1631  f  dilated tubules  hyperplasia  development incomplete  NSL  NSL  NA  ND 
hyperplasia  adenocarcinoma 
TM1696  m  dilated tubules  hyperplasia  NA  hyperplasia  diffuse malignant  hyperplasia  ND 
hyperplasia  mastocytosis  hypertrophy 
TM1723  f  NSL  NSL  development incomplete/  hyperplasia  focal malignant  NA  hyperplasia 
nonlactating  mastocytosis 
adenocarcinoma 
TMllF1 f  NSL  NSL  fully developed  NSL  NSL  NA  ND 
lactating 
wild-type f  NSL  NSL  fully developed  ND  NSL  NA  ND 
* Offspring from TM1165 
NA, not applicable;  ND, not done; NSL, no significant lesions. 
The Journal of Cell Biology, Volume 122,  1993  202 Figure 3. Histology and immunohistology of lung and kidney from MMTV LTR c-erbB-2 transgenic and wild-type mice. (A) Lung from 
a wild-type mouse. (B) Lung from a transgenic mouse. Note the severe pseudopapillary proliferation of  bronchial epithelial cells obstructing 
the bronchial  lumen. Alveoli are normal.  (C) Immunostalning  of the same lung as in R  Note the characteristic  membrane staining for 
the c-erbB-2 protein in the hyperplastic bronchial epithelial cells. (D) Kidney from a wild-type mouse. (E) Kidney from a transgenie mouse. 
Note the mnltifocal dilatation  of the tubules (arrowhead). Atypical renal tubular epithelial proliferation  with marked basophilia.  Some 
glomeruli at the cortico-medullary  junction are enlarged and hyperceUular (arrow). (F) Immunostalnlng of the same kidney as in E. Note 
that the membrane staining is strictly localized to the hyperplastic epithelial cells. The adjacent normal tubules are not stained. Bars: (A, 
C, and F)  100/zm; (B, D, and E) 200/~m. 
higher  magnification that the tubular  epithelial  cells were 
markedly basophilic and atypical with increased cell volume 
and enlarged nuclei (data not shown). Normal tubules were 
seen adjacent to these lesions. Glomeruli also showed abnor- 
malities  which  were found  predominantly  at the  cortico- 
medullary junction.  Here, the glomeruli were enlarged in 
size  and  hypercellular,  with  loss  of glomerular  capillary 
loops and mesangium.  Towards the renal capsule the glo- 
meruli appeared normal (data not shown). Immunohistochem- 
ical analysis showed very strong c-erbB-2 expression through- 
out  these  hyperplastic  lesions.  There  was  no  staining  of 
histologically normal renal structures detectable (Fig. 3 F). 
St6cklin et al. Pathogenicity of Activated c-erbB-2  203 Figure 4. Histology and immunohistology of mammary glands and epididymis of MMTV LTR c-erbB-2 transgenic and wild-type mice. 
(A) Mammary tissue from a wild-type virgin mouse. Note the presence of mammary ducts (arrow) interspersed through the mammary 
fat pad. Lymph node (arrowhead). (B) Mammary tissue  from a virgin transgenic  mouse. Mammary glandular ducts are largely missing 
from the fat tissue.  Lymph node (arrowhead). (C) ~clenocarcinoma from a virgin transgenic mouse. Note the presence of neoplastic  pleo- 
morphic epithelial  cells narrowing the glandular lumen. (D) Mammary tissue  from a parous wild-type mouse. Note the regular pattern 
of a fully developed alveolar-lobular structure with secreted  milk in the alveoli.  (E) Hyperplasia of the mammary gland from a parous 
transgenic mouse. Note the atypical, severe proliferation of epithelial  cells completely filling the glandular lumen. (F) Immunostaining 
of the same mammary gland as in E. Note the characteristic membrane staining for c-erbB-2 in the hyperplastic  epithelium.  (G) Immuno- 
histology of a mammary gland from a parous transgenic  mouse.  Note the nonuniform expression  pattern of the c-erbB-2 protein.  The 
hyperplastic  nodule shows a strong surface staining,  whereas the adjacent  morphologically normal ducts appear negative  (arrow).  (H) 
Epididymis from a wild-type mouse (8 wk). Note the lumina of the tubules contain many spermatozoa. (J) Epididymis from a transgenic 
mouse (8 wk). Tubular lumens are extremely dilated.  Note the focal pseudopapillary epithelial hyperplasia.  Spermatozoa are largely miss- 
ing in the tubular lumen. (K) Immunohistology of the same epididymis as in ~  The staining pattern for c-erbB-2 reveals partially intense, 
and partially faint staining  throughout the hyperplastic  epithelium.  Bars: (A, B, H, and J) 200 ~m; (C, E, and F) 50/~m; (D, G, and 
K)  100 ~m. 
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Predominant membrane staining, indicative for cells with 
high c-erbB-2 protein expression at the cell surface was seen 
at higher magnification  (data not shown). These results differ 
from the ones obtained with the activated MMTV LTR c-neu 
transgene (Muller et al.,  1988;  Bouchard et al.,  1989, see 
discussion). 
Histopathological Evaluation of the Mammary Glands 
The analysis of the mammary tissue of the transgenic mice 
was particularly important in light of the frequent involve- 
ment of the c-erbB-2 gene in human breast cancer, and the 
conflicting observations made in studies with MMTV LTR 
c-neu transgenic mice. The most striking finding of  the histo- 
logical evaluation of mammary glands of several transgenic 
female mice was the abnormal development and structure of 
the mammary tissue and its infiltration by hyperplastic or 
neoplastic nodules. Histopathology on the virgin mammary 
glands from TM1631  showed that the gland was dominated 
by the presence of a typical adenocarcinoma infiltrating the 
mammary fat pad (Fig. 4 C). There was a marked atypical 
proliferation of the alveolar ductal  epithelium with pleo- 
morphic  changes and numerous mitotic figures.  In  some 
areas of the tumor pseudopapillary proliferation narrowed 
the ductal lumen. The adjacent mammary fat tissue was only 
sparsely scattered with ductal structures, this is in contrast 
to their frequent appearance in wild-type virgin mammary 
glands (Fig. 4, A and B). 
Two parous transgenic mice, TM1624 and TM1723,  lost 
their pups shortly after birth, suggesting lactation deficiency. 
Histological examination of their mammary glands revealed 
completely  underdeveloped  mammary  glands  composed 
mainly of fat tissue interspersed by only a few ducts and mul- 
tiple infiltrating hyperplastic nodular lesions. The mammary 
glands lacked the typical lobular-alveolar structure of the 
lactation state, in particular the secretory, lactating alveoli 
were absent. Similar underdeveloped mammary glands were 
seen in MMTV LTR int-3 transgenic mice (Jhappan et al., 
1992). 
At higher magnification the hyperplastic nodular lesions 
showed severe,  atypical proliferation of the alveolar-ductal 
mammary epithelium partially, or completely filling the duc- 
tal lumen, and in some areas even forming solid cords of 
cells (Fig. 4 E). In TM1624 the hyperplastic nodules seemed 
not yet fully transformed. In contrast, in TM1723 one out of 
three histologically evaluated mammary glands revealed the 
characteristics of an adenocarcinoma. The pleomorphic epi- 
thelial ceils infiltrate the skeletal muscle. The adenocarci- 
noma was adjacent to atypical hyperplasia. These growth 
disturbances were always localized and never involved the 
epithelial cells of the entire mammary gland. Interspersed in 
these hyperplastic lesions were a few normal ducts. These 
results  indicate  the  stochastic  appearance  of  mammary 
tumors in the MMTV LTR c-erbB-2 mice. 
Immunohistochemical analysis of these mammary glands 
showed strong c-erbB-2 staining in the hyperplastic lesions 
(Fig.  4  F)  and  the  adenocarcinornas.  The  staining  was 
limited to the proliferating epithelial ceils. No or only very 
weak immunostaining was detected in the remaining normal 
mammary ducts (Fig. 4 G). These results are in contrast to 
reports in which the transgene was found to be uniformly ex- 
pressed at high levels in both malignant and normal tissue 
of transgenic mice (Stewart et al., 1984; l.exler et al., 1986; 
Sinn et al.,  1987; Tsukamoto et al.,  1988; Bouchard et al., 
1989). 
Consequences of  c-erbB-2 Expression in the Male 
Reproductive Tract 
Dramatic changes of the male reproductive tract were al- 
ready observed  macroscopically. Abnormal,  bilateral  en- 
largement of the epididymis, vas deferens, and seminal vesi- 
cles was noted in two transgenic males, TM1623 and TM1696. 
Subsequent histopathology of these lesions revealed severe 
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of atypical pseudopapillary epithelial hyperplasia causing an 
abnormal architecture. Immunohistochemical  analysis showed 
c-erbB-2  expression throughout these extensive epithelial 
proliferation. The staining does not seem homogeneous. The 
pseudopapillary proliferations show weaker staining than the 
less proliferating areas (Fig. 4 K). No staining was observed 
in epididymis of wild-type control animals (data not shown). 
The impediment of spermatogenesis probably explain the 
sterility of these animals. None of the male transgenic mice 
in our study sired a litter. Similar results have been reported 
in transgenic mice expressing the c-neu (Miiller et al., 1988; 
Bouchard et al., 1989), N-ras (Mangues et al., 1990),  int-2 
(Miiller et al., 1990) and int-3 (Jhappan et al., 1992) genes 
under the control of the MMTV LTR. 
Phenotypic Abnormalities in the Salivary, Harderian, 
and Lacrimal Glands, the Spleen and the Mast Cells of 
the Transgenic Mice 
In addition to mammary tumors and hyperplasia of the epi- 
thelium in kidney, lung, and male reproductive tracts, the 
MMTV LTR c-erbB-2 mice exhibited additional growth ab- 
normalities, primarily in organs and cells known to use the 
MMTV LTR promoter/enhancer (Choi et al., 1987; Stewart 
et  al.,  1988;  Henrard  et  al.,  1988;  Ross  et  al.,  1990). 
MMTV LTR c-erbB-2 mice developed malignant mast cell 
neoplasia and hypertrophy or hyperplasia of the epithelium 
in the salivary glands (Table HI). The Harderian gland of  ani- 
mal TM 1723 revealed severe bilateral hyperplasia of  the epi- 
thelium that arose adjacent to morphologically normal tis- 
sue. The c-erbB-2 protein showed a nonuniform expression 
pattern, and distinct staining was only detected in the hyper- 
plastic nodule.  Adjacent normal glandular cells were not 
stained (data not shown). Dissection of the lacrimal gland 
of  the same animal showed abnormalities of  the glandular ar- 
chitecture. Severe  hyperplasia and dysplasia were seen al- 
most throughout the entire gland. A  solid-like pattern oc- 
curred showing cytological atypia and suggesting a possible 
malignant transformation (data not shown). 
Splenomegaly was another abnormality found in two trans- 
genic mice, TM 1624 and TM 1696. Histologically, the red 
pulp of the spleen was markedly hypercellular and exten- 
sively infiltrated with mastocytes. In both animals this obser- 
vation correlated with high levels of MMTV LTR c-erbB-2 
transgene expression (Table II). Several other organs were 
infiltrated by mastocytes, but  not as  dramatically as  the 
spleen. In one animal, TM 1723, only small foci of masto- 
cytes were noted, sparsely scattered in the red pulp of the 
spleen. 
Abnormalities were found on histological examination of 
the salivary gland. Multiple small foci of epithelial hyper- 
trophy or hyperplasia were scattered throughout the salivary 
gland in three transgenic mice examined. Immunochemistry 
revealed that only the hyperplastic or hypertrophic lesions 
expressed the transgene at a moderate level (data not shown). 
No expression was seen in the surrounding normal tissue. 
Discussion 
Amplification and overexpression of the c-erbB-2  gene oc- 
curs frequently in human adenocarcinomas of the breast, 
ovary,  lung,  stomach, and salivary gland (Hynes,  1992). 
These findings have demarcated this growth factor receptor 
as a potent oncogene and attracted considerable attention to 
the  study of its  function.  Biochemical experiments  have 
defined the enzymatic properties of the intrinsic tyrosine 
specific protein kinase and its substrates.  Transfection ex- 
periments have shown its oncogenic potential in cultured 
cells and transgenic mouse models have been developed to 
assess in vivo the consequences of ectopic expression. 
Two publications have described the introduction of the 
activated rat c-neu oncogene under the control of  the MMTV 
LTR into transgenic mice (Muller et al., 1988; Bouchard et 
al., 1989). The most striking difference between these stud- 
ies and the one reported here is the viability of the transgenic 
animals. Our transgenic mice died early. In the kidney, focal 
dilatation and atypical proliferation of the renal tubular epi- 
thelial cells and lesions in the glomeruli were observed. In 
the lung, bronchial and bronchiolar epithelial proliferation 
caused  narrowing  of the  bronchial  lumen  and  possibly 
suffocation. These preneoplastic lesions in kidney and lung 
most probably caused organ failure. For these reasons it was 
not possible to establish lines. This has not been reported for 
the MMTV LTR c-neu mice described earlier. Differences 
in the biological activities of the activated rat c-neu and the 
human c-erbB-2 gene could be responsible. The drastic ab- 
errations of kidney and lung and the early death of these 
transgenic animals limit their usefulness for experimental 
therapeutic anti-tumor studies. The severe premalignant le- 
sions observed here, however, might indicate that c-erbB-2 
overexpression is not only correlated with the development 
of cancer, but might also underlie other conditions. 
Our observations concerning the effects of transgene ex- 
pression in the mammary gland are important complements 
to the observations reported earlier by Muller et al. (1988) 
and Bouchard et al. (1989). These authors obtained concur- 
ring, as well as contradictory results. Both studies reported 
hypertrophy  and  hyperplasia  in  the  salivary  glands  and 
epididymis, but differed significantly  in their findings and in- 
terpretations of the c-neu  effects on the mammary gland. 
Muller et al.  (1988) reported that the transgenic mice de- 
velop polyclonal, synchronously arising adenocarcinomas 
that involve the entire epithelium in each gland and con- 
cluded that the expression of the activated c-neu oncogene 
is sufficient to induce malignant transformation in a single 
step.  Since independently and asynchronously arising tu- 
mors appeared late after birth at multiple sites Bouchard et 
al. (1989) concluded that c-neu expression was important for 
initiation and maintenance, but not sufficient for tumor for- 
marion. They claimed that high levels of  transgene RNA was 
present in morphologically normal tissue and preceeded the 
appearance of stochastically arising mammary tumors. Our 
immunohistochemical  analysis shows heterogeneity of  trans- 
gene expression.  The c-erbB-2  protein can barely be de- 
tected in normal mammary tissue. High expression of the 
c-erbB-2 protein and hyperplasia are concomitant. The non- 
uniform expression of the transgene is not restricted to the 
mammary tissue. We made equivalent observations in all or- 
gans  examined.  Ectopic  c-erbB-2  expression  cannot  be 
tolerated and is invariably associated with severe cellular 
hyperplasia in a variety of epithelial cell types. The powerful 
dominant phenotype ofc-erbB-2 expression in the transgenic 
mice might be a reflection of the potent oncogenic activity 
observed in so many human tissues. 
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able  from malignant  tumors.  Tumors  found,  e.g.,  in  the 
mammary gland, still develop stochastically. Our results do 
not support a model which suggests that the expression of the 
activated  c-erbB-2 gene is sufficient for malignant transfer- 
marion. Oncogenes regulated by the MMTV LTR promoter 
have been introduced and expressed in transgenic mice. The 
predominant phenotype  observed was the development of 
mammary carcinoma. A high incidence was found in trans- 
genie mice expressing c-myc (Stewart et al., 1984; Leder et 
al., 1986), v-Ha-ms (Sinn et al., 1987; Tremblay et al., 1989), 
int-1  (Tsukamoto et al.,  1988),  activated  c-neu (Mfiller et 
al., 1988; Bouchard et al., 1989), ret (Iwamoto et al., 1990), 
TGF-ot (Matsui et al., 1990), N-ms (Mangues et al., 1990), 
and int-3 (Jhappan et al.,  1992). In all cases the tumor for- 
marion appeared  to be a stochastic event and tumors were 
clonal in origin. 
The tumors which occur in the transgenic mice described 
here,  however,  were found at an earlier age than  in most 
other studies cited above. This early onset indicates that the 
c-erb-2  oncogene very  strongly predisposes cells for neo- 
plastic  transformation  and  that  mammary  epithelial  cells 
seem to be most sensitive.  This sensitivity might in turn be 
related to the extensive inhibition of mammary gland differ- 
entiation.  Strongly proliferating cells were observed in the 
mammary glands of the transgenic animals at a few weeks 
of age, but the glandular tree never developed properly.  It is 
reasonable  to  assume  that  cells  responsible  for the  early 
stages  of mammary  development  are  stimulated  in  their 
proliferation, but inhibited in their differentiation potential. 
These cells seem particularly  prone for transformation. 
In all tissues analyzed,  we consistently observed hyper- 
plastic,  c-erbB-2  expressing  cells  coexisting  side-by-side 
with phenotypically normal, non-expressing cells. The ques- 
tion  which  arises  from  these  observations  concerns  the 
mechanism by which a transgene, present in an integrated 
state in all somatic cells, is subject to differential  regulation 
in a particular tissue. It is possible that nuclear factors neces- 
sary for the transcription  of the MMTV  LTR are not uni- 
formly distributed in the cells of individual tissues. Since the 
transcription  of the MMTV LTR is regulated by steroid hor- 
mone receptors, it is conceivable that these receptors are not 
homogeneously expressed or activated in all cells of a partic- 
ular organ.  In addition to the steroid receptors other tran- 
scription  factors  regulating  the  MMTV  LTR  have  been 
identified (Lefebre et al., 1991; Yanagawa et al., 1991; Mink 
et al.,  1992).  Interestingly, epigenetic heterogeneity in the 
hormonal response has also been observed in tissue culture. 
The dose-dependent induction of a transfected  MMTV LTR 
construct in fibroblasts was found to result from changes in 
the number of responding cells, rather than from changes in 
the expression level of individual cells (Ko et al.,  1990). 
The glucocorticoid-dependent  transactivation of the MMTV 
LTR is cell-cycle dependent (Hsu et al., 1992). It is possible 
that the transcription of the MMTV LTR, and consequently 
the expression of the c-erbB-2 protein, might initially be re- 
stricted to a small subset of cells. These cells maintain the 
MMTV  LTR in an active configuration, either due to "the 
formation  of a  stable  transcription  complex"  (Ko  et  al., 
1990) or through a feedback control exerted by the activated 
c-erbB-2 receptor. The expressing cells proliferate and give 
rise to the hyperplasric  phenotype observed in the different 
tissues. 
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